Novo Nordisk A/S - share repurchase programme
Bagsværd, Denmark, 07 February 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023.
Under the programme initiated 1 February 2023, Novo Nordisk will repurchase B shares for an amount up to DKK 5.6 billion in the period from 1 February 2023 to 2 May 2023.
Since the announcement of the programme, the following transactions have been made:
|1 February 2023||96,564||946.18||91,366,945|
|2 February 2023||95,000||919.51||87,353,550|
|3 February 2023||99,000||927.88||91,860,092|
|6 February 2023||97,000||952.87||92,428,242|
|Accumulated under the programme||387,564||363,008,829|
The details for each transaction made under the share repurchase programme are published on novonordisk.com.
Transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 4,470,056 B shares in the period from 1 February 2023 to 6 February 2023. The shares in these transactions were not part of the Safe Harbour repurchase programme.
With the transactions stated above, Novo Nordisk owns a total of 27,549,005 B shares of DKK 0.20 as treasury shares, corresponding to 1.2% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 28 billion during a 12-month period beginning 1 February 2023. As of 6 February 2023, Novo Nordisk has since 1 February 2023 repurchased a total of 387,564 B shares at an average share price of DKK 936.64 per B share equal to a transaction value of DKK 363,008,829.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 54,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and YouTube.
Contact for further information
|Ambre Brown Morley|
+45 3079 9289
|Natalia Salomao Abrahao (US)|
+1 848 304 1027
|Daniel Muusmann Bohsen|
+45 3075 2175
|Jacob Martin Wiborg Rode|
+45 3075 5956
|David Heiberg Landsted |
+45 3077 6915
|Mark Joseph Root (US) |
+1 848 213 3219
Company announcement No 9 / 2023
Upcoming Life Sciences Events
- March 2023
- Zurich: Swiss Nordic Bio 2023
- April 2023
- Basel: Swiss Biotech Day 2023
- Brussels: Cell and Gene Therapy Summit
Latest company news
BD and A*STAR collaborate to Advance Ultra-High Dimensional Analysis in Flow Cytometry for Immunology Research
iOnctura awarded UK's MHRA Innovation Passport for entry into innovative licensing and access pathway (ILAP)
Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023